financetom
Personal Finance
financetom
/
Personal Finance
/
COVID-19 health insurance policies — Check premiums of 'Corona Kavach' and 'Corona Rakshak'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
COVID-19 health insurance policies — Check premiums of 'Corona Kavach' and 'Corona Rakshak'
Dec 28, 2022 4:51 AM

Reports of a massive surge in COVID-19 infections in China, led by an Omicron sub-lineage BF.7, has given rise to apprehensions over the possibility of a spill-over effect in India. While the fear of catching the disease has led to a doubling of daily vaccination rates, it's important to see if we have adequate health insurance or not to meet the expenses related to the treatment. The lives of many people have been affected earlier by the disease.

Live TV

Loading...

As per Insurance Regulatory and Development Authority in India's (IRDAI's) mandate, existing health insurance policies now include coverage for COVID-19-related hospitalisation. Apart from this, there are several customized health insurance policies for COVID-19 too available in the market which can be considered.

In 2020, IRDAI asked all insurance companies to come out with 'Corona Kavach' and 'Corona Rakshak' policies to help consumers protect themselves from the financial burden of Covid-19 medical bills. Both corona health insurance policies are designed to cover you against the expense of COVID-19 treatment at a low cost.

About Corona Kavach

Corona Kavach is a standard indemnity-based COVID-19 policy for a term of three-and-a-half months, six-and-a-half months and nine-and-a-half months with a sum insured ranging from Rs 50,000 to Rs 5 lakh (in multiples of Rs 50,000).

These policies have common coverage across the industry. However, there is some difference in the way insurers have priced the product.

About Corona Rakshak

This is a standard benefit-based policy. If a policyholder is hospitalised for a minimum of 72 hours (3 days) after testing Covid-19 positive at any government-approved testing centre, the insurance company pays a lump sum payment equal to the sum insured under this insurance policy.

It is a regular fixed benefit plan in which policyholders will receive 100 percent of the insured amount.

Here's a difference between 'Corona Kavach' and 'Corona Rakshak':

FeaturesCorona Kavach PolicyCorona Rakshak Policy
Sum InsuredRs 50,000-Rs 2.5 LakhRs 50,000-Rs 5 Lakh
CoverageFloaterIndividual
Hospitalisation hours24 hours72 hours
Type of CoverIndemnity BasedBenefit Based
PaymentAs per hospitalization expensesPaid in lumpsum upon diagnosis

Now, let's take a look at the difference in the premium between Corona Kavach and Corona Rakshak policies:

Corona Kavach Health Premiums for 30-year-old with SI of Rs 2.5 Lakh
Insurer3.5 months6.5 months9.5 months
Bajaj Allianz Corona Kavach Plan6158201025 
Iffco Tokio Corona Kavach Plan7668701166
Future Generali Corona Kavach Policy410517624
New India Assurance Corona Kavach Policy863911959
Max Bupa Corona Kavach Policy523697871 
Corona Rakshak Health Premiums for 30-year-olds with SI of Rs 2.5 lakh
Insurer3.5 months6.5 months9.5 months
Star Corona Rakshak Policy384646155192
Future Generali Corona Rakshak Policy321416512
Iffco Tokio Corona Rakshak Policy10281795 2406

(Note: This is from Policybazaar. However, the insurance aggregator mentioned that this is only for reference purposes. One should refer to policy wording before purchase)

How comprehensive health insurance policy is different from these plans?

A comprehensive health insurance plan, as the name suggests, covers all major illnesses, including seasonal illnesses and accidents, up to the sum insured for which the customer has opted. These policies also cover all kinds of respiratory diseases, which means they cover coronavirus, provided the affected person does not have COVID-19 when purchasing the policy.

On the other hand, COVID-19 policies are specific to the disease.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Hold Opinion On Shares Of Netapp, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Netapp, Inc.
May 31, 2024
11:20 AM EDT, 05/31/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target to $107 from $98 on 15x our CY 25 EPS view of $7.15, below its five-year historical average. We lift our FY 25 (Apr.) EPS...
Research Alert: CFRA Keeps Hold Opinion On Shares Of Costco Wholesale Corporation
Research Alert: CFRA Keeps Hold Opinion On Shares Of Costco Wholesale Corporation
May 31, 2024
08:55 AM EDT, 05/31/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target price to $846 from $770, 47x our FY 25 (Aug.) EPS of $18.01 (up from $17.32; FY 24 up to $16.42 from $16.04) vs. 38x five-year...
Research Alert: CFRA Lowers Opinion On Shares Of Nordstrom, Inc. To Sell From Hold
Research Alert: CFRA Lowers Opinion On Shares Of Nordstrom, Inc. To Sell From Hold
May 31, 2024
08:30 AM EDT, 05/31/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month price target of $16, based on 8.0x our FY 25 (Jan.) EPS estimate and in line with peers average forward P/E multiple. We maintain our FY...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Veeva Systems Inc.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Veeva Systems Inc.
May 31, 2024
10:55 AM EDT, 05/31/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $36 to $194, reflecting a P/E of 31.5x our FY 2025 EPS estimate, below VEEV's recent historical average to reflect a slower growth trajectory...
Copyright 2023-2026 - www.financetom.com All Rights Reserved